 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Audit |
|
|
|
| Symptomatic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
Registered Charity 269736
|
|
|
Symptomatic Audit
The Breast Cancer Clinical Outcome Measures (BCCOM) Project
The annual ABS at BASO breast screening audit demonstrated variations in the management of screen-detected breast cancer across the UK. Since its inception in 1997, the audit has brought about major improvements in clinical practice. However, over 70% of all new breast cancer cases are initially detected symptomatically and the majority of these cases are not incorporated into a national audit due to the lack of reliable, accurate data. "BCCOM will extend the audit process to cover symptomatic breast cancers"
AIMS of BCCOM
- To audit across the UK the treatment of symptomatic breast cancer
- To compare management with published national standards and targets
- To measure against treatment' hypotheses/gold standards
- To inform the setting of future standards
- To obtain complete and accurate outcome measures including survival
HOW are BCCOM aims achieved?
- By setting up routine methods to conduct a retrospective audit of the treatment of primary symptomatic (female and male) breast cancer in the UK. This involves tapping into existing data sources such as the data currently collected by cancer registries and individual clinicians, or Hospital Episodes Statistics (HES).
- By establishing a complete and accurate dataset of symptomatically detected breast cancers and their management.
- By using the data collected to generate clinical outcome measures for individual breast services in order to compare current practice with the recommended guidelines.
The BCCOM project is funded by a 3-year grant from Breakthrough Breast Cancer.
For further information, please contact catherine.lagord@wmciu.nhs.uk
Click here to download PDF version of BCCOM Annual report
Visit the BCCOM webpage
|
|
